B. Riley Principal Merger Corp. II (BMRG.U), announced the pricing of their $175 million SPAC IPO this evening, downsized from $200 million, and the units are expected to begin trading tomorrow, Wednesday, May 20th, under the symbol NYSE: BMRG.U.
B. Riley Principal Merger Corp. II, is being sponsored by B. Riley FBR, the bank, and will be focusing on a broad range of industries, but within the $400 million to $1 billion enterprise value range. Additionally, B. Riley II will be led by Bryant Riley, as Chairman, and Daniel Schribman, as CEO and Director.
Total SPAC deal count for 2020 year-to-date is now 26 with $7.901 billion in gross proceeds raised. The offering is anticipated to close on Friday, May 22, 2020.
B. Riley FBR, Inc., is acting as the sole book-running manager for this offering. Winston & Strawn LLP and Ellenoff Grossman & Schole LLP, were Issuer’s Counsel and Underwriter’s Counsel, respectively. Marcum LLP, acted as auditor.
AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...
At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...
Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...
At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...
Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...